Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05302284 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Aug 31, 2022, no change to tracked fieldsv4-v5
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 30, 2022 to Jun 14, 2022 · Site details revised at 2 of 2 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Apr 30, 2022 to Jun 14, 2022
    • Site details revised at 2 of 2 sites
  3. Interventions: Carboplatin (Drug), Cisplatin (Drug), Gemcitabine (Drug), RC48-ADC (Drug), Triplizumab (Drug) to Carboplatin (Drug), Cisplatin (Drug), Gemcitabine (Drug), RC48-ADC (Drug), Toripalimab (Drug) Study description revised · Study title revisedv2 Show 2 more changesShow less
    • Study description revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.
Trial Details
NCT Number NCT05302284
Lead Sponsor RemeGen Co., Ltd.
Conditions Urothelial Carcinoma, HER2-expressing
Enrollment 452 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov